BIOV Bioventus Inc. Class A Common Stock (MM)

GAITHERSBURG, Md., Aug. 9 /PRNewswire-FirstCall/ -- BioVeris Corporation (NASDAQ:BIOV) reported today the financial results for its fiscal first quarter ended June 30, 2006, and filed its Quarterly Report on Form 10-Q with the Securities and Exchange Commission. BioVeris recorded revenues of $4.1 million for the fiscal 2007 first quarter ended June 30, 2006, compared to $4.9 million in the corresponding prior year period. Revenues include product sales of $3.6 million for the quarter ended June 30, 2006, compared to $4.6 million in the corresponding prior year period. Product sales in the current quarter were from $1.5 million of biosecurity products and $2.1 million of products for the life science market. Changes in product sales in the current quarter reflect the change of orders and product deliveries, which are based on customers' requirements. Product costs were $2.4 million (66% of total product sales) for the quarter ended June 30, 2006 compared to $2.0 million (45% of total product sales) in the corresponding prior year period. The current year increase includes approximately $100,000 of costs incurred in connection with detection module upgrades for certain existing customers. Product costs also increased due to higher service costs related to detection modules. Research and development expenses decreased to $4.3 million for the quarter ended June 30, 2006 from $4.8 million in the corresponding prior year period. Research and development expenditures decreased in the current period due primarily to lower facilities and personnel costs. Research and development expenses primarily relate to ongoing development costs and product enhancements associated with vaccines, the M-SERIES family of products, development of new assays and research and development of new systems and technologies, including point-of-care products. Selling, general and administrative expenses were $6.2 million for the quarter ended June 30, 2006 and $5.7 million in the corresponding prior year period. The increase in selling, general and administrative costs in the quarter ended June 30, 2006 was primarily attributable to an increase in professional and outside service costs related to continued compliance with Section 404 of the Sarbanes-Oxley Act of 2002, compensation expense associated with the implementation of SFAS 123R, and to fees incurred in conjunction with the review of Roche's compliance with the restrictions in its license to BioVeris' ECL technology. BioVeris' net loss for the quarter ended June 30, 2006 was $7.4 million ($0.27 per common share, compared to a net loss of $6.7 million ($0.25 per common share) for the quarter ended June 30, 2005. At June 30, 2006, BioVeris had cash, cash equivalents and short-term investments of $61.5 million. BioVeris Corporation is a global integrated health care company developing proprietary technologies in diagnostics and vaccinology. The Company is dedicated to the development and commercialization of innovative products and services for healthcare providers, their patients and their communities. BioVeris is headquartered in Gaithersburg, Maryland. Further information about BioVeris is available at http://www.bioveris.com/. This press release contains forward-looking statements within the meaning of the federal securities laws that relate to future events or BioVeris' future financial performance. All statements in this press release that are not historical facts, including any statements about consolidation of future financial information and future financial or operational plans are hereby identified as "forward-looking statements." The words "may," "should," "will," "expect," "could," "anticipate," "believe," "estimate," "plan," "intend" and similar expressions have been used to identify certain of the forward-looking statements. In this press release, BioVeris has based these forward-looking statements on management's current expectations, estimates and projections and they are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements. Such forward-looking statements should, therefore, be considered in light of various important factors, including changes in BioVeris' strategy and business plans; BioVeris' ability to develop and introduce new or enhanced products; BioVeris' ability to enter into new collaborations on favorable terms, if at all; and changes in general economic, business and industry conditions. The foregoing sets forth some, but not all, of the factors that could impact upon BioVeris' ability to achieve results described in any forward-looking statements. A more complete description of the risks applicable to BioVeris is provided in the Company's filings with the SEC available at the SEC's web site at http://www.sec.gov/. Investors are cautioned not to place undue reliance on these forward-looking statements. Investors also should understand that it is not possible to predict or identify all risk factors and that neither this list nor the factors identified in BioVeris' SEC filings should be considered a complete statement of all potential risks and uncertainties. BioVeris has no obligation to publicly update or release any revisions to these forward- looking statements to reflect events or circumstances after the date of this press release. (Financial data follows.) BioVeris Corporation Consolidated Statement of Operations (In thousands, except per share data) (Unaudited) Three Months Ended June 30, June 30, 2006 2005 REVENUES: Product sales $ 3,590 $ 4,580 Royalty income 498 309 Total 4,088 4,889 OPERATING COSTS AND EXPENSES: Product costs 2,384 2,048 Research and development 4,262 4,765 Selling, general, and administrative 6,202 5,681 Total 12,848 12,494 LOSS FROM OPERATIONS (8,760) (7,605) INTEREST INCOME 1,201 1,318 OTHER, NET 187 (381) NET LOSS $ (7,372) $ (6,668) Net loss per common share (basic and diluted) $ (0.27) $ (0.25) COMMON SHARES OUTSTANDING (basic and diluted) 26,880 26,728 BioVeris Corporation Consolidated Balance Sheets (In thousands) (Unaudited) June 30, March 31, 2006 2006 ASSETS CURRENT ASSETS: Cash and cash equivalents $ 37,266 $ 29,693 Short-term investments 24,226 39,938 Accounts receivable, net 2,920 3,360 Inventory, net 6,476 5,429 Other current assets 2,329 2,508 Total current assets 73,217 80,928 Equipment and leasehold improvements, net 3,340 3,456 OTHER NONCURRENT ASSETS: Note receivable, net 5,857 5,666 Technology licenses 14,869 15,356 Other 447 447 TOTAL ASSETS $ 97,730 $ 105,853 LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES: Accounts payable and accrued expenses $ 5,055 $ 5,362 Accrued wages and benefits 1,267 1,862 Other current liabilities 1,739 1,520 Total current liabilities 8,061 8,744 NONCURRENT DEFERRED LIABILITIES 135 546 Total liabilities 8,196 9,290 SERIES B PREFERRED STOCK, 1,000 shares designated, issued and outstanding 7,500 7,500 STOCKHOLDERS' EQUITY: Preferred stock, par value $0.01 per share, 15,000,000 shares authorized, issuable in series: Series A, 600,000 shares designated, none issued - - Common stock, par value $0.001 per share, 100,000,000 shares authorized, 27,239,000 and 27,238,000 shares issued and outstanding at June 30, 2006 and March 31, 2006, respectively 27 27 Additional paid-in capital 204,593 205,997 Deferred compensation - (1,688) Accumulated other comprehensive loss (47) (128) Accumulated deficit (122,539) (115,145) Total stockholders' equity 82,034 89,063 TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 97,730 $ 105,853 DATASOURCE: BioVeris Corporation CONTACT: George Migausky of BioVeris Corporation, +1-301-869-9800, ext. 2013; or investors: Jonathan Fassberg of The Trout Group, +1-212-477-9007, ext. 16; or media: Paul Caminiti or Andrew Cole of Citigate Sard Verbinnen, +1-212-687-8080 Web site: http://www.bioveris.com/

Copyright